Grünenthal has recently acquired Valinor Pharma in an all-stock transaction, gaining global rights to Movantik® (naloxegol). Movantik, previously owned by Valinor, has seen significant growth in the USA under the Apollo Care platform, leading to a 150% increase in revenue and an all-time high EBITDA in the first quarter of 2024.
Valinor’s CEO, Todd N. Smith, expressed pride in the value created for patients and shareholders through this acquisition. The innovative commercial platform developed by Valinor, in collaboration with Apollo Care, has been instrumental in driving prescription growth, reducing gross-to-net value, and cutting operating costs.
The success of Movantik under Valinor’s ownership has been a testament to the transformative strategies implemented by the team. Since 2023, Movantik has shown consistent growth, resulting in significant net revenue in the first quarter of 2024. Clarke B. Futch, Chairman of Valinor, emphasized the impact of strategic planning and execution in rejuvenating Movantik’s performance in mature markets.
Financial advisors RBC Capital Markets, LLC and Wells Fargo played key roles in the Valinor acquisition, while legal counsel was provided by McDermott Will & Emery LLP. Valinor’s mission is to deliver value to patients, healthcare providers, and investors by focusing on patient service and successful commercialization of therapies in today’s market.
Apollo Care, the company behind the successful implementation of integrated solutions for patient access and analytics, continues to drive innovation in the pharmaceutical industry. Based in Chicago, Illinois, Apollo Care aims to optimize gross-to-net costs and improve patient outcomes through purpose-built technology.
The acquisition of Valinor by Grünenthal signifies a major milestone in the pharmaceutical industry, with the potential for future growth and innovation. To learn more about Valinor and Apollo Care, visit their respective websites at http://www.valinorrx.com and http://www.apollocare.com, or connect on LinkedIn for updates on their latest developments.
Source link
